aTyr Pharma, Inc. (ATYR)
ATYR Stock Price Chart
Explore aTyr Pharma, Inc. interactive price chart. Choose custom timeframes to analyze ATYR price movements and trends.
ATYR Company Profile
Discover essential business fundamentals and corporate details for aTyr Pharma, Inc. (ATYR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
7 May 2015
Employees
56.00
Website
https://www.atyrpharma.comCEO
Sanjay S. Shukla
Description
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.
ATYR Financial Timeline
Browse a chronological timeline of aTyr Pharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.15.
Earnings released on 15 May 2026
EPS came in at -$0.11 surpassing the estimated -$0.16 by +31.25%.
Earnings released on 5 Mar 2026
EPS came in at -$0.14 surpassing the estimated -$0.18 by +22.22%.
Earnings released on 6 Nov 2025
EPS came in at -$0.26 falling short of the estimated -$0.20 by -30.00%, while revenue for the quarter reached $190.00k , beating expectations by +850.00%.
Earnings released on 7 Aug 2025
EPS came in at -$0.22 falling short of the estimated -$0.18 by -22.22%.
Earnings released on 7 May 2025
EPS came in at -$0.17 surpassing the estimated -$0.19 by +10.53%.
Earnings released on 13 Mar 2025
EPS came in at -$0.18 surpassing the estimated -$0.23 by +21.74%.
Earnings released on 7 Nov 2024
EPS came in at -$0.23 falling short of the estimated -$0.22 by -4.55%.
Earnings released on 13 Aug 2024
EPS came in at -$0.23 falling short of the estimated -$0.22 by -4.55%.
Earnings released on 2 May 2024
EPS came in at -$0.23 surpassing the estimated -$0.24 by +4.17%, while revenue for the quarter reached $235.00k , beating expectations by +540.90%.
Earnings released on 14 Mar 2024
EPS came in at -$0.25 falling short of the estimated -$0.24 by -4.17%.
Earnings released on 30 Sept 2023
EPS came in at -$0.20 surpassing the estimated -$0.23 by +13.32%, while revenue for the quarter reached $353.00k , missing expectations by -76.47%.
Earnings released on 30 Jun 2023
EPS came in at -$0.22 surpassing the estimated -$0.28 by +19.68%.
Earnings released on 31 Mar 2023
EPS came in at -$0.29 surpassing the estimated -$0.35 by +18.50%.
Earnings released on 9 Mar 2023
EPS came in at -$0.26 surpassing the estimated -$0.48 by +45.83%, while revenue for the quarter reached $10.39m , beating expectations by +2.81k%.
Earnings released on 10 Nov 2022
EPS came in at -$0.46 surpassing the estimated -$0.46 by +0.72%.
Earnings released on 15 Aug 2022
EPS came in at -$0.44 falling short of the estimated -$0.38 by -15.18%.
ATYR Stock Performance
Access detailed ATYR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
